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An early engagement survey was conducted,
followed by sites signing a Confidentiality Disclosure
Agreement (CDA), receiving the protocol synopsis,
and conducting a full site feasibility questionnaire.
The CDA process was completed in 7 European
countries within 12 days.
The four-step process until full feasibility report was
completed in a total of over 25 sites Europe-wide







Paediatric clinical trial networks have made many advances over the last few years (1-3). In Europe, the Innovative Medicines Initiative (IMI2)-funded
conect4children (c4c) initiative has promoted innovation and standardization within all levels of paediatric drug development (1,4). Its predecessor in Belgium
was the FWO-SBO project SAFEPEDRUG (IWT 130033) which started in 2014 to develop and implement new standards for early phase paediatric drug
development (3). Across the Atlantic, I-ACT for Children (Institute for Advanced Clinical Trials for Children) has progressed vastly in the paediatric clinical
network. I-ACT for Children is a US-based non-profit organization for the advancement of paediatric clinical trials (5). For the first time, a trans-Atlantic
collaboration was formed between I-ACT for Children and the Belgian Paediatric Clinical Research Network (BPCRN) which is one of the 20 countries within
c4c (6).
In the elaboration of an industry sponsored study, both networks joined hands to perform the international early-engagement, CDA and full feasibility report
in 7 countries within the c4c network.
Take Home Message
1. Over the past 5 years, networks such as conect4children (c4c) and I-ACT for Children have made
substantial improvements in paediatric clinical trials.
2. By shortening the timeline from early engagement to full expert-reviewed feasibility for a pan-
European network, paediatric clinical trials become more attractive for industry.
3. Such platforms and their collaborations are essential to achieve substantial improvement in















































• Connection with national representatives
• Personal connection with sites (weekly close contact due to multitude of studies with national hubs and sites) 
• Efficient contact: 
• Problem resolution speed
• No language barrier
Pan-European network: 
• Completed majority of tasks before deadline
• High response rate in follow-up questions
• Summary completed with expert review per site
Site inclusion
• Earlier start initiation visits
• Bottlenecks of the sites identified and anticipated
• Option of network follow-up after SFQ
Study initiation
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